Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing the safety of a new injectable drug called AMG 609 in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if the drug is safe and well-tolerated when given as a single dose.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Who Is on the Research Team?
MD
Principal Investigator
Amgen
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single ascending dose of AMG 609 or placebo subcutaneously
Follow-up
Participants are monitored for safety and tolerability after receiving the dose
What Are the Treatments Tested in This Trial?
Interventions
- AMG 609
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amgen
Lead Sponsor
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London